openPR Logo
Press release

EPO Biomarkers Market Revenue and Value Chain 2016-2026

07-27-2016 12:05 PM CET | Health & Medicine

Press release from: Future Market Insights

Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.

EPO Biomarkers Market: Drivers & Restraints

The prime drivers for the market include growing incidence of cancers and renal diseases. Changes in lifestyle and improper eating habits contribute to pancreatic and endocrine cancers, which often lead to severe anaemia, where external erythropoietin infusion is required. Other drivers for the EPO biomarker market is technological advancement in devising proprietary testing methods apart from tried and tested ones.

Restraints for the market include lack of availability of skilled labour and sufficient quality controlled testing laboratories in most countries in less developed regions. Insufficient R&D in identification of biomarkers due to adoption of cost cutting measures in European regions is expected to restrain proper quantitative assessment of drugs and their therapeutic efficacy in blood. This could also hamper progress of ongoing clinical trials and proper stratification of patients.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1382

EPO Biomarkers Market: Segmentation

EPO Biomarkers is classified on the basis of biomarker, indication, testing method and end user type:

Based on biomarker type, the global EPO Biomarkers is segmented into the following:

Recombinant human erythropoietin

Erythropoietin alfa

Erythropoietin beta

Erythropoietin zeta

Erythropoietin theta

Darbepoietin alfa

Based on indication, the global EPO Biomarkers is segmented into following:

End stage renal disorder

Cancers

Rheumatoid arthritis

AIDS

Others

Based on end users, the global EPO Biomarkers is segmented into the following:

Diagnostic centers

Hospitals

Ambulatory care and surgical centers

EPO Biomarkers Market: Overview

EPO biomarker market is account to rise in value during the forecast period. Due to expansion in the product segment of EPO biomarkers the market share will be rising with a promising rate, also with the increase in demand for diagnosis and treatment of widely spread chronic disease the EPO market is expected to grow with a promising CAGR during the forecast period. Biologic drug industry is investing on R&D and the key players are focusing on increasing their production capacity for EPO biomarkers.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1382

EPO Biomarkers Market: Region-wise Outlook

Considering all potential geographic regions, EPO biomarkers market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific and Middle East & Africa. North America is been dominating in the EPO biomarkers due to rise in acceptance for bio-similar weakly followed by Western and Eastern Europe, Asia Pacific has a dominating presence in EPO biomarker market and most of the key players are locally producing the EPO biomarkers, that is enhancing their market share and product reach. There is a good opportunity for Japan in EPO biomarker market. The emerging regions in Asia Pacific, Middle East and Africa holds promising future for rise in EPO biomarker market, due to increase in awareness towards the chronic disease and increase in population simultaneously.

EPO Biomarkers Market: Key Players

Shandong Kexing Bioproducts Co., Ltd., Amgen Inc., Ranbaxy Laboratories Ltd, Johnson & Johnson, Roche Holding AG, Sigma-Aldrich, Thermo Fisher Scientific, Hospira Inc., Biocon, Teva Pharmaceutical Industries Ltd.,

Browse Full Report@ http://www.futuremarketinsights.com/reports/epo-biomarkers-market

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release EPO Biomarkers Market Revenue and Value Chain 2016-2026 here

News-ID: 352167 • Views:

More Releases from Future Market Insights

Glass Bottles Market Set to Soar at 5.70% CAGR, Empowering Manufacturers with Sustainable Growth
Glass Bottles Market Set to Soar at 5.70% CAGR, Empowering Manufacturers with Su …
The global glass bottles market is entering a transformative phase, projected to expand from USD 44.9 billion in 2025 to USD 78.2 billion by 2035, representing a CAGR of 5.7%. This trajectory underscores a robust opportunity for manufacturers to align operations with rising demand for sustainable and premium packaging solutions across diverse industries. Sales in 2024 reached USD 42.4 billion, reflecting a consistent growth momentum that signals confidence in market
Passive Temperature-Controlled Packaging Market Set to Grow at 5.48% CAGR in India, Unlocking New Opportunities for Manufacturers
Passive Temperature-Controlled Packaging Market Set to Grow at 5.48% CAGR in Ind …
The Indian passive temperature-controlled packaging solutions market is poised for significant expansion, with projected growth at a CAGR of 5.48% over the next decade. Valued at USD 13,865 million globally in 2024, the industry is anticipated to nearly double to USD 28,137 million by 2034. This growth trajectory presents manufacturers with an unparalleled opportunity to cater to evolving market demands across pharmaceuticals, food and beverage, chemicals, and biotechnology sectors. Meeting Critical
Bag in Tube Market Set to Grow 6.7% in India, Unlocking New Opportunities for Manufacturers
Bag in Tube Market Set to Grow 6.7% in India, Unlocking New Opportunities for Ma …
The global bag in tube market is entering a phase of transformative growth, expected to rise from USD 5.6 million in 2024 to USD 8.7 million by 2034, representing a steady CAGR of 4.5%. The market's expansion reflects broader trends in sustainable packaging, convenience, and material innovation. For manufacturers, this presents a compelling opportunity to adopt forward-looking strategies that align with evolving consumer preferences and regulatory demands. Sustainability and Consumer Convenience
India's Packaging Barrier Film Market Poised for 6.5% Growth Through 2034
India's Packaging Barrier Film Market Poised for 6.5% Growth Through 2034
The Packaging Barrier Film market is entering a decade of sustained growth, with its valuation expected to reach USD 24.5 billion by 2034 from USD 18.8 billion in 2024, reflecting a steady CAGR of 2.7%. For manufacturers, this market offers unparalleled opportunities to capitalize on evolving consumer needs, regulatory shifts, and technological advancements in packaging solutions. With the rapid production of electronic goods worldwide, packaging barrier films are increasingly being recognized

All 5 Releases


More Releases for EPO

Erythropoietin (EPO) Treatment Market Outlook and Future Projections for 2030
The erythropoietin (epo) treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the
Erythropoietin (EPO) Treatment Market, Global Outlook and Forecast 2025-2033
Summary: The Global Erythropoietin (EPO) Treatment Market was valued at US$9242 million in 2022 and is projected to reach US$ 19070 million by 2033, at a CAGR of 6.2% during the forecast period. The Global Erythropoietin (EPO) Treatment Market was valued at US$ 9.24 billion in 2022 and is expected to reach US$ 14.07 billion by 2029, growing at a 6.2% CAGR. EPO is primarily used to treat anemia caused
Erythropoietin (EPO) Market Analysis & Growth Insights 2024-2033
The Business Research Company recently released a comprehensive report on the Global Erythropoietin (EPO) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
EPO Biomarkers Market Size, Share | Forecast 2032
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global EPO Biomarkers Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Erythropoietin (EPO) Drugs Market: An Overview
Introduction: Erythropoietin (EPO) is a glycoprotein hormone that plays a crucial role in regulating red blood cell production (erythropoiesis) in the body. EPO drugs are synthetic versions of this hormone used to treat anemia, particularly in patients with chronic kidney disease (CKD), cancer, HIV, and other critical conditions that impact red blood cell production. EPO drugs help maintain adequate hemoglobin levels, improving the quality of life for patients by reducing the
Global EPO Biomarkers Market Research and Forecast 2018-2023
Global EPO biomarkers market size, market intelligence, market trends, research and analysis report by biomarker (erythropoietin alfa, beta, zeta, theta, recombinant human erythropoietin, darbepoetin alfa) by applications (end-stage renal disorder, cancers, rheumatoid arthritis, aids, myelodysplastic syndrome, neurology, hematology) forecast 2018-2023 According to the OMR analysis, the global EPO biomarkers Market is expected to grow impressively during 2018-2023. The global EPO biomarkers market is segmented on the basis of biomarker type, applications,